Caron Jacobson, MD
Enriched profileMedical Director, Immune Effector Cell Therapy Program; Associate Professor of Medicine · Dana-Farber Cancer Institute
Caron Jacobson is Medical Director, Immune Effector Cell Therapy Program; Associate Professor of Medicine at Dana-Farber Cancer Institute. OpenAlex indexes 577 publications with 23,849 citations (h-index 61); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Caron A. Jacobson, MD, is Medical Director, Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute, Boston, MA. The public record shows 577 publications with 23,849 citations (h-index 61), centered on Lymphoma. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 18 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lymphoma
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Axi-cel in CNS Lymphoma
Sponsor: Dana-Farber Cancer Institute
- Rituximab + Immunotherapy in Follicular Lymphoma
Sponsor: Dana-Farber Cancer Institute
- Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202521 payments$23,526openpaymentsdata.cms.gov ↗
- ADC THERAPEUTICS AMERICA, INC.Program year202510 payments$14,259openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
43.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor43.2%Acyclovir100%Part D≥17 patientsAnti-infectives
28.4%Short-acting sulfonamides28.4%Sulfamethoxazole-Trimethoprim100%Part D≥17 patientsCancer & immunology
21.3%Kinase inhibitor21.3%Brukinsa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Clinical cancer research
Clinical Trial2026 - Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal of clinical oncology
Article2025 - Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Journal of clinical oncology
Clinical Trial2025 - Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Journal of clinical oncology
Article2024
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/caron-jacobson-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
thebloodline.org/096-e96
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thebloodline.org ↗ - Other
onclive.com/authors/caron-a.-jacobson,-md,-dana-farber-cancer-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
Columbia University College of Physicians & Surgeons
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Columbia University/New York-Presbyterian Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Fellowship
Hematology/Oncology, Dana-Farber/Partners CancerCare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Principal Investigator
multiple CAR T-cell clinical trials in B-cell non-Hodgkin lymphoma, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- LLS (Blood Cancer United) Scholar in Clinical Research grant
for CAR T-cell therapy research in CNS lymphoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →defycancer.dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Member
Dana-Farber/Harvard Cancer Center (DF/HCC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dfhcc.harvard.edu ↗ - Physician
Brigham and Women's Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Guest
"How CAR T-cell Therapy Gives Hope to Cancer Patients," The Bloodline with Blood Cancer United (podcast)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thebloodline.org ↗ - Featured speaker
"CAR-T Cell Therapy for Lymphoma: Updates and Progress" (Dana-Farber physician video)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - Panelist
"Aggressive Lymphoma Panel Discussion" (Dana-Farber physician video)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - Featured speaker profile
VJHemOnc video/research platform
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center